Pharmacogenetics and Individualized Therapy

by Maitland-van der Zee, Anke-Hilse; Daly, Ann K.

• ISBN13: 9781118116494
• ISBN10: 1118116496
• Edition: 1st
• Format: eBook
• Copyright: 2012-08-09
• Publisher: Wiley

Summary

This resource provides thorough coverage of pharmacogenetics and its impact on pharmaceuticals, therapeutics, and clinical practice. It opens with the basics of pharmacogenetics, including drug disposition and pharmacodynamics. The following section moves into specific disease areas, including cardiovascular, psychiatry, cancer, asthma/COPD, adverse drug reactions, transplantation, inflammatory bowel disease, and pain medication. Clinical practice and ethical issues make up the third section, with the fourth devoted to technologies like genotyping, genomics, and proteomics. In the fifth part, chapters discuss the impact of key regulatory issues on the pharmaceutical industry.

Author Biography

ANKE-HILSE MAITLAND-van der ZEE, PhD, is Associate Professor of Pharmacogenetics/Pharmacogenomics at Utrecht University, the Netherlands.

ANN K. DALY, PhD, is Professor of Pharmacogenetics at Newcastle University, UK.

Table of Contents

PREFACE vii

CONTRIBUTORS ix

1. Pharmacogenetics: A Historical Perspective 1
Ann K. Daly

PART I PHARMACOGENETICS: RELATIONSHIP TO PHARMACOKINETICS AND PHARMACODYNAMICS

2. Pharmacogenetics in Drug Metabolism: Role of Phase I Enzymes 15
Vita Dolz!an

3. Pharmacogenetics of Phase II Drug Metabolizing Enzymes 81
Ingolf Cascorbi

4. Pharmacogenetics of Drug Transporters 101
Henriette E. Meyer zu Schwabedissen, Markus Grube, and Heyo K. Kroemer

5. Pharmacogenetics of Drug Targets 149
Ann K. Daly and Maria Arranz

PART II PHARMACOGENETICS: THERAPEUTIC AREAS

6. Cardiovascular Pharmacogenetics 185
Bas J. M. Peters, Anthonius de Boer, Tom Schalekamp, Olaf H. Klungel, and Anke-Hilse Maitland-van der Zee

7. Pharmacogenetics in Psychiatry 215
Evangelia M. Tsapakis, Sarah Curran, Ruth I. Ohlsen, Nora S. Vyas, Katherine J. Aitchison, and Ann K. Daly

8. Pharmacogenetics in Cancer 251
Sharon Marsh

9. Pharmacogenetics of Asthma and COPD 271
Ellen S. Koster, Jan A. M. Raaijmakers, Anke-Hilse Maitland-van der Zee, and Gerard H. Koppelman

10. Pharmacogenetics of Adverse Drug Reactions 295
Ann K. Daly, Martin Armstrong, and Munir Pirmohamed

11. Pharmacogenomics of Inflammatory Bowel Diseases 323
Alexander Teml, Susanne Karner, Elke Schaeffeler, and Matthias Schwab

12. Pharmacogenetics of Pain Medication 353
Jo¨rn Lo¨tsch

PART III PHARMACOGENETICS: IMPLEMENTATION IN CLINICAL PRACTICE

13. Ethical and Social Issues in Pharmacogenomics Testing 377
Susanne Vijverberg, Toine Pieters, and Martina Cornel

PART IV DEVELOPMENTS IN PHARMACOGENETIC RESEARCH

14. High-Throughput Genotyping Technologies for Pharmacogenetics 403
Beatriz Sobrino and Angel Carracedo

15. Developments in Analyses in Pharmacogenetic Datasets 415
Alison A. Motsinger-Reif

PART V PHARMACOGENETICS: INDUSTRY AND REGULATORY AFFAIRS

16. Applications of Pharmacogenetics in Pharmaceutical Research and Development 439
Daniel K. Burns and Scott S. Sundseth

17. Role of Pharmacogenetics in Registration Processes 461
Myong-Jin Kim, Issam Zineh, Shiew-Mei Huang, and Lawrence J. Lesko

PART VI CONCLUSIONS

18. Pharmacogenetics: Possibilities and Pitfalls 479
Anke-Hilse Maitland-van der Zee and Ann K. Daly

INDEX 485